Pharmacological treatment of cognitive impairments in Alzheimer's disease

Autonomic and Autacoid Pharmacology

Volumn 26, Issue 1, 2006, Pages 46-49

  Danchev, N ^a   Nikolova, I ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID PRECURSOR PROTEIN; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE; TACRINE;

AGNOSIA; ALZHEIMER DISEASE; ANOREXIA; APHASIA; APRAXIA; CHOLINERGIC ACTIVITY; CLINICAL FEATURE; COGNITIVE DEFECT; CONFERENCE PAPER; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIAGNOSTIC APPROACH ROUTE; DIARRHEA; DRUG INDUCED DISEASE; DRUG STRUCTURE; HUMAN; LIVER DISEASE; MEMORY DISORDER; NAUSEA; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; SENILE PLAQUE; VOMITING;

EID: 33644955242     PISSN: 14748665     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (10)

1. BIRKS, J. & FLICKER, L. (2003). Selegiline for Alzheimer's disease. Cochrane Database Syst. Rev., CD000442.
2. CLEGG, A., BRYANT, J., NICHOLSON, T., MCINTYRE, L., DE BROE, S., GERARD, K. et al. (2001). Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review. Health Technol. Assess., 5, 1-137.
3. CUMMINGS, J.L., FRANK, J.C., CHERRY, D., KOHATSU, N.D., KEMP, B., HEWETT, L. et al. (2002). Guidelines for managing Alzheimer's disease: part I. Assessment. Am. Fam. Physician, 65, 2263-2272.
4. CUMMINGS, J.L., FRANK, J.C., CHERRY, D., KOHATSU, N.D., KEMP, B., HEWETT, L. et al. (2002). Guidelines for managing Alzheimer's disease: Part II. Treatment. Am. Fam. Physician, 2525-2534.
5. JOST, B.C.& GROSSBERG, G.T. (1996). The evolution of psychiatric symptoms in Alzheimer's disease: a natural history study. J. Am. Geriatr. Soc., 44, 1078-1081.
6. LOVESTONE, S., GRAHAM, N., & HOWARD, R. (1997). Guidelines on drug treatments for Alzheimer's disease. Lancet, 350, 232-233.
7. SANO, M., ERNESTO, C., THOMAS, R.G., KLAUBER, M.R., SCHAFER, K., GRUNDMAN, M. et al. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med., 336, 1216-12122.
8. TABET, N., BIRKS, J., GRIMLEY EVANS, J., ORREL, M. & SPECTOR A. (2003). Vitamin E for Alzheimer's disease. Cochrane Database Syst. Rev., CD002854.
9. T'VELD, B.A., RUITENBERG, A., HOFMAN, A., LAUNER, L.J., VAN DUIJN, C.M., STIJNEN, T. et al. (2001). Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med., 345, 1515-1521.
10. WHITEHOUSE, P.J. (1997). Genesis of Alzheimer's disease. Neurology, 48 (5 Suppl 7), S2-S7.